MPM BioImpact

🤝 A*STAR & MPM BioImpact: Building Biotech Spinoffs Together A*STAR is excited to partner with MPM BioImpact to venture build globally investible biotech spinoffs. Thank you Dr Ansbert Gadicke, M.D., Founder and Managing Partner at MPM BioImpact and Dr David Kolesky, Principal at MPM BioImpact for the engaging fireside chat with Irene Cheong, Senior Executive Director, A*STAR Innovation & Enterprise (Venture Creation & Growth and Human Health & Potential) on venture-building, and for sharing valuable insights with our aspiring scientist-founders! Over 100 A*STAR scientists and ecosystem partners including ClavystBio, EDBI Pte Ltd, Enterprise Singapore, SGInnovate and National Research Foundation Singapore joined us for today’s fireside chat and networking lunch. A*STAR will continue to collaborate with our ecosystem partners to support the growth of biotech spinoffs and pave the way for groundbreaking #biotech innovations. Stay tuned for updates and be part of this remarkable venture building journey with us! Wendy Wu Jie Yee-Chia Yeo Su Ling Yeo Daphne Wong #DeepTechVentureBuilding #StartUpJourney #Innovation #CreatingGrowth #ASTARforEnterprise #ASTARforIndustry

We are proud to share that our CEO Ivan Cheung has been named to the 2024 #TIME100HEALTH list by TIME, which recognizes the 100 most influential people in global health. “Ivan has demonstrated a relentless commitment to translating scientific breakthroughs into tangible solutions that benefit patients worldwide. The well-deserved recognition by TIME underscores his outstanding contributions to public health and exemplifies his visionary leadership and unwavering dedication to improving the lives of patients.” - Detlev Biniszkiewicz, PhD, Managing Director at MPM BioImpact and Chairman of NextPoint’s Board of Directors. Under Ivan’s leadership, NextPoint is advancing a new class of precision immuno-oncology and tumor-directed therapeutics targeting the novel B7-H7 axis, so that we can improve treatment options for cancer patients including those who do not benefit from PD-1/L1 therapy. Read the full announcement at https://nextpointtx.com/. 

Today, Reunion Neuroscience announced the closing of a $103 million Series A financing co-led by MPM BioImpact and Novo Holdings. The financing will support the RECONNECT Phase 2 clinical trial for RE104 in #postpartumdepression and expansion into other psychiatric indications of high unmet need, including adjustment disorder in #cancer. RE104 is a proprietary, clinical-stage serotonergic psychedelic drug candidate designed as a safe, fast-acting, short duration therapy for underserved #mentalhealth disorders. Read the press release: https://bit.ly/3Wj5fyF

I was quoted in The Wall Street Journal this morning in an article, "Investors Flock Back to Biotech After a Long, Cold Spell". After a three year meltdown in the markets, fingers crossed that our industry will start to get attention for its great progress. https://lnkd.in/gc95nasc

  Today we announced the close of our oversubscribed $80 million Series C financing co-led by Deerfield Management Company and Droia Ventures, with significant participation from Galapagos NV (Euronext & NASDAQ: GLPG) as a strategic investor, and contributions from new and existing investors including DCVC Bio, MPM Capital, and RA Capital Management.  We also announced the first participant dosed with FMC-376, the first therapeutic candidate discovered with the Frontier™ Platform.   Learn more here: https://lnkd.in/esgxPc7X #biotech, #precisionmedicines, #oncology

Firefly is excited to share that we've closed a $94M Series A to advance Degrader Antibody Conjugates (DACs) that combine the unique strengths of ADCs with selective protein degraders. We're funded by Versant Ventures, MPM BioImpact, Decheng Capital, and Eli Lilly & Co.  https://lnkd.in/grEAF9U8

Today we are proud to announce the closing of a $42.5M Series B Extension for a total Series B raise of $122.5M to advance our two immuno-oncology clinical programs, NPX267 and NPX887, as well as propel the development of additional therapeutic modalities that target the novel HHLA2 tumor antigen. “We are advancing a diverse set of assets into clinical trials to exploit HHLA2’s role as both a novel immune checkpoint and a tumor-targeting mechanism. We are thrilled to pioneer a new class of monotherapies to treat both hot and cold tumors.” - Ivan Cheung, CEO.   We are grateful for the support our new and existing investors, including lead investor Catalio Capital Management. Read the press release to learn more at https://nextpointtx.com/.